pcn poster

Posters

The Incidence and Economic Burden of Extrapyramidal Symptoms in Patients with Schizophrenia Treated with Atypical Antipsychotics

Background: Extrapyramidal symptoms (EPS), including movement disorders, tremors, and muscle contractions are common side effects of atypical antipsychotic (AAP) drugs in patients with sc...

Aditi Kadakia , MS;

Huan Huang , PhD;

Carole Dembek , MS;

Rhys Williams , PhD;

Justine Kent , MD;

Brenna Brady , PhD;

10/08/2020

Post hoc Analysis of the Efficacy and Safety of Lemborexant in Adults with Insomnia Disorder and Depression History

Introduction: Study 303 (SUNRISE-2; NCT02952820) evaluated lemborexant (LEM) efficacy in subjects with insomnia. This post-hoc analysis examined sleep outcomes in the subgroup of subjects...

Larry Culpepper , MD;

Andrew Krystal , MD;

Jane Yardley , PhD;

Kate Pinner , MSc;

Naoki Kubota ;

Margaret Moline , PhD;

Jess Amchin , MD, JD;

Norman Atkins Jr., MBA, PhD;

Manoj Malhotra , MD;

Andrew Nierenberg , MD, MGH;

10/08/2020

The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System

Objective: A previous study demonstrated that patients with schizophrenia consumed substantial healthcare resources in an integrated healthcare system. This study evaluated healthcare uti...

Rohan Mahabaleshwarkar , PhD;

Jesse Fishman , PharmD;

Charmi Patel , BS , RN, BSN, MPH;

Todd Blair ;

Dee Lin , PharmD, MS;

Timothy Hetherington , MS;

Carmella Benson , MSc, MS, MSHP;

Pooja Palmer ;

Kruti Joshi , MPH, MD;

Constance Krull , MSPH;

Oleg Tcheremissine , MD;

10/08/2020

Safety and Tolerability of Aripiprazole Lauroxil 2-Month Formulation With 1-Day Initiation for Treatment of Schizophrenia in the ALPINE Study

Objective: Evaluate safety and tolerability of an aripiprazole lauroxil (AL) 2-month regimen using 1-day initiation in patients hospitalized for acute exacerbation of schizophrenia and tr...

Ilda Bidollari , MD, MBA;

Alexa Vasios , MS, MPH;

Amy Claxton , PhD;

10/08/2020

Post Hoc Analyses of Treatment History on SHP465 Mixed Amphetamine Salts Extended-Release Responses in Adult Attention-Deficit/Hyperactivity Disorder

In 2 placebo-controlled studies of adults with attention-deficit/hyperactivity disorder (ADHD), SHP465 mixed amphetamine salts (MAS) extended-release significantly reduced ADHD-Rating Sca...

Valerie Arnold , MD;

Eric Lloyd , MS;

Salah Foraida , MD, MS;

10/08/2020

The Clinical Utility of Combinatorial Pharmacogenomic Testing for Patients with Depression: A Meta-Analysis

Background: Pharmacogenomic (PGx) testing is a potential tool to inform clinicians’ treatment decisions for patients with Major Depressive Disorder (MDD). However, there is mixed evidence...

Ken Yu , MS;

Holly Johnson , PhD;

Krystal Brown , PhD;

Michael Jablonski , PhD;

Bryan Dechairo , PhD;

Lisa Brown , PhD;

Oliver Vranjkovic , PhD;

James Li , MS, PhD;

10/08/2020

Safety Profile of Adjunctive Pimavanserin in the ENHANCE Study, a Phase 3 Trial for the Potential Treatment of Schizophrenia in Patients With an Inadequate Response to Antipsychotic Treatment

Many patients with schizophrenia do not respond fully to antipsychotic treatment despite adherence. Evidence supporting polypharmacy is limited and adding another antipsychotic is associa...

Dragana Bugarski-Kirola , MD, MBA, MSc;

Srdjan Stankovic , MD, MSPH;

I-Yuan Liu , MSc;

Rene Nunez , MD;

Ramzey Odetalla , PA, MSc;

Mohammed Bari , MD;

Istvan Bitter , MD, PhD, DSc;

Peter Feldman , PhD;

10/08/2020

Reduction in Anxiety Symptoms in Patients With Postpartum Depression (PPD) Treated With the Neuroactive Steroid Brexanolone Injection (BRX)

Background: Anxiety is a prominent symptom and comorbidity of PPD. Post-hoc analyses of an integrated dataset from three BRX PPD trials evaluated effects of BRX on anxiety symptoms using ...

Kristina Deligiannidis , MD;

Robert Riesenberg , MD;

Kemi Bankole , PhD;

Haihong Li , PhD;

Stephen Kanes , MD, PhD;

Samantha Meltzer-Brody , MD;

Brian Werneburg , PhD;

C. Neill Epperson , MD;

David Rubinow , MD;

10/08/2020

Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-month, Open-label Extension Study

Background: SEP-363856 is a novel non-D2 receptor antagonist, and preclinical data suggest that agonism at trace amine associated receptor 1 (TAAR1) and the serotonin 5-H1A receptor contr...

Robert Goldman , PhD;

Hailong Cheng , PhD;

Seth Hopkins , PhD;

Kenneth Koblan , PhD;

Justine Kent , MD;

Antony Loebel , MD;

10/08/2020

The Clinical Implications of Weight Gain on Depression and Anxiety in Mental Health Treatment

Individuals with severe mental illness are at increased risk for weight gain due to side effects from atypical antipsychotics and mood stabilizers, sedentary lifestyle, and social isolati...

Philip Harvey , PhD;

Raymond Kotwicki , MD, MPH, DFAPA;

Alexandra Balzer , MPH;

10/08/2020

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products